ãã€ãªã»ãã«ã¹ã±ã¢ã«é¢ããèªç±ãªè©±é¡ãšéè«
47
ã¡ã³ããŒ
32
æçš¿
å¥åº·èšºæã®çµæãã©ãèªãããåå¿è åãã«ãŸãšããŠã¿ãŸãããç¹ã«HbA1cãšLDLã³ã¬ã¹ãããŒã«ã®åºæºå€ã«ã€ããŠã䞻治å»ããæããŠããã£ãããšãã·ã§ã¢ããŸãã
仿¥ã®å®éšã®æ§åãã·ã§ã¢ããŸããæããPCRã®ã»ããã¢ãããååŸã¯ã²ã«é»æ°æ³³åããã€ãªç ç©¶ã£ãŠå°éãªäœæ¥ã®é£ç¶ã§ããããã³ãããããã«åºãæã®åã³ã¯æ Œå¥ãããããå¡©åºé åã®ç¢ºèªäœæ¥ã«å ¥ããŸãã
仿¥ã®å®éšã®æ§åãã·ã§ã¢ããŸããPCRè£ çœ®ã®ã»ããã¢ããããã²ã«é»æ°æ³³åãŸã§ããã€ãªç ç©¶ã£ãŠå°éãªäœæ¥ã®é£ç¶ã§ãããçµæãåºãæã®åã³ã¯æ Œå¥ã§ãã
å»åŠéš5幎çã§ãåºç€ç ç©¶ã«èå³ããããŸãããèšåºãæšãŠãããã§ããMD-PhDããã°ã©ã ãæ€èšããŠããŸãããå 茩æ¹ã®çµéšãèãããŠãã ãããç¹ã«ãç ç©¶ãšèšåºã®äž¡ç«ã¯çŸå®çã§ããããïŒ
WHOãçºè¡šãã2025幎äžçä¿å¥çµ±èšã¬ããŒããææç察çã®é²æ©ã¯èŠããããã®ã®ãNCDsïŒéæææ§çŸæ£ïŒã®è² æ ãå¢å€§ãç¹ã«ã¡ã³ã¿ã«ãã«ã¹ãšè¥æºã®äžççãªå¢å åŸåãé¡èãæ¥æ¬ã®å»çã·ã¹ãã ã¯äžççã«èŠãŠãé«ãè©äŸ¡ãåããŠããŸãããé«éœ¢åãžã®å¯Ÿå¿ãæå€§ã®èª²é¡ãšããŠææãããŠããŸãã
www.who.int
ãã€ãªãåµè¬ã®è©±é¡ã«èå³ãåºãŠããã®ã§ãããä¿¡é Œã§ããæ å ±ãã©ãã§è¿œãã°ããã®ãè¿·ã£ãŠããŸããäžè¬ã®ãã¥ãŒã¹ãµã€ãã ãšèŠåºãã倧ãããªããšãå€ããŠãçãããæ®æ®µãã§ãã¯ããŠããæ å ±æºãããã°æããŠãã ããã
äºé²å»åŠã«èå³ããã£ãŠåå ããŸããã å»çããã€ãªã®ãã¥ãŒã¹ã¯é£ãããã§ä»ãŸã§é¿ããŠããã®ã§ãããããã®èšäºã¯å°éçšèªãåã¿ç ããŠãã£ãŠèªã¿ãããã§ããã ãã°ããã¯èªãå°éã«ãªãããã§ããããããããé¡ãããŸãã
æåŠäŒã®ãã¹ã¿ãŒã§ãAIçæç»åã§ãããšæ³šéãå ¥ãããã座é·ãããããå°ãå ·äœçã«æžããæ¹ãããããšææãããŸããã æµ·å€åŠäŒã ãšAI䜿çšã®ãã£ã¹ã¯ããŒãžã£ãŒãå¿ é åãããæµãã§ãããæ¥æ¬ã®èšåºç³»åŠäŒã ãšãŸã ã¬ã€ãã©ã€ã³ã远ãã€ããŠããªãå°è±¡ã§ãã çãããããŒã«åã»ã¢ãã«åã»ããã³ããèŠæšã»ä¿®æ£ã®æç¡ãã©ããŸã§æžãããŠããŸããã瀟å çºè¡šãšåŠäŒçºè¡šã§ç·åŒãããããªãããã®åºæºã䌺ãããã§ãã
现èã®æèšãå·»ãæ»ãââãããªç ç©¶ã«å€§æè£œè¬ãããŒãæµã蟌ãã§ããŸãã ãäœãèµ·ããã èåé転ãç®æããã€ãªäŒæ¥NewLimitããçŽ435ååïŒ3åãã«ïŒã調éãããšçºè¡šããŸãããå ±å嵿¥è ãã«å ãã補è¬å€§æã€ãŒã©ã€ã»ãªãªãŒãåºè³ã«åå ããŠããŸãã ãäœã®æè¡ãã åå°ã«ããã®ã¯ãå±±äžå åããç®èãªã©ã®çްèãåæåããŠiPS现èãäœããããŒãã«è³ã®æè¡ã§ããNewLimitã¯ãããå¿çšãã现èãå®å šã«åæåãããè¥ãç¶æ ããžå°ãã ãæ»ãããšãçããŸããå瀟ã¯ããã®èèã®çްèã§ãèåã«é¢ããææšãè¥ãæ¹åãžåããããšããããŒã¿ã瀺ããŠããŸãã ããªãç¯ç®ãªã®ãã ãããŸã§èåç ç©¶ã¯ãå®éšå®€ã®è©±ããšèŠãããã¡ã§ãããããã«è£œè¬å€§æãè³éãšãã€ãã©ã€ã³ã§åŸãçŸã«ã€ãããšã¯ãç 究段éããåµè¬ããã°ã©ã ãžç§»ãåå²ç¹ãæå³ããŸãããã ãã人ã§ã®æ²»ç广ãå®å šæ§ã¯ããããã®æ€èšŒèª²é¡ã§ãã åºå žïŒBioPharma DiveïŒ2026-06-02ïŒãNewLimitå ¬åŒããã° â»æ¬èšäºã¯æ å ±æäŸãç®çãšãããã®ã§ã蚺æãæ²»çæ¹éã¯å¿ ã䞻治å»ã«çžè«ããŠãã ããã
www.biopharmadive.com
Potioneã䜿ãå§ããŠããããã«ã¹ã±ã¢ã»ãã€ãªç³»ã®ãã¥ãŒã¹ãèœåçã«æ¢ãç¿æ £ãã€ããŸããã ä»ã®ãšãããã§ãã¯ããŠããã®ã¯: - NHK ãµã€ãšã³ã¹ZERO - ãã·ã§ãžãªã®èšäº - MITãã¯ãããžãŒã¬ãã¥ãŒ (ããŸã«) - Potione ã®ç·šéãã¥ãŒã¹ ä»ã«ã¿ãªãããæ¥åžžçã«èŠãŠãããµã€ãããã¥ãŒã¹ã¬ã¿ãŒãPodcastãããã°æããŠãã ããã è±èªã®ãœãŒã¹ã§ãOKã§ãã
ããæè¿ããã€ãªé¢é£ã®çºè¡šãç«ãŠç¶ãã§ãæ£çŽè¿œããããã®ã倧å€ã§ãã æšæ¥ãŸã§å®é𿮵éã ãšæã£ãŠãããã®ããæ°ã¥ãã°èšåºã®è©±ã«ãªã£ãŠããããå°éå®¶ã§ã¯ãªãã®ã§ãã©ããæ¬åœã«å€§ããªäžæ©ã§ãã©ãããŸã åæã®è©±ãªã®ããæž©åºŠæãã€ããã®ãé£ãããšæããŠããŸãã ãã®ã³ãã¥ããã£ã®ããã¥ãŒã¹ãå·éã«æŽçããŠãããé°å²æ°ãæ°ã«å ¥ã£ãŠããŸããã¿ãªããã¯æ°ããçºè¡šãèŠããšãããŸãã©ãã確èªããŠããŸããã
仿¥Potioneã§ç޹ä»ãããŠããLife Biosciencesã®ER-100ã®è©±ãèªãã§ãæ¹ããŠæ°ã«ãªã£ãŠããŸãã ãªããã°ã©ãã³ã°ã现èè¥è¿ãç ç©¶ã®æèã§ããèåãã®ãã®ãæ²»ç察象ãšããŠæ±ãããšãã衚çŸãæè¿ããèŠãããã«ãªããŸããã ç ç©¶ãšããŠã¯çãéã£ãŠãããšæãäžæ¹ãæ£è ã»å®¶æã®æèŠãšããŠãç æ°ã§ã¯ãªãå éœ¢ãæ²»ãããšããèšãæ¹ã«ã¯å°ãéåæããããŸããNAIONãç¹å®ã®çŸæ£ã察象ã«ããèšåºãšããŠã¯çè§£ã§ããŸããããã®åŸã©ããŸã§ãäºé²ãããã¢ã³ããšã€ãžã³ã°ãã®æ¹åã«è¡ãã®ããçããã¯ã©ãèŠãŠããŸããã ç§åŠçãªãã§ã¢ãªè°è«ãã§ããã°ããããã§ãã
èåãé·å¯¿ã®åéã«å€§ããªæè³ãå ¥ã£ãŠãããã¥ãŒã¹ãèŠããšãæåŸ ååãæ éã«èŠããæ°æã¡ååã§ãã ãéãéãŸãããšèªäœã¯ç ç©¶ãé²ãåŸæŒãã«ãªããšæãäžæ¹ã§ãéå°ãªæåŸ ããããæ¹åã«è¡ããªããšãããªãšãæããŸããã¿ãªããã¯ããããæµããã©ããªãµãã«åãæ¢ããŠããŸããã
ç±³ãã€ãªäŒæ¥ Life Biosciences ãéçºãã ER-100 ããFDAããåã®äººäœèšåºè©Šéšèš±å¯ãåããŸãããäžçã§åããŠãéšåçãªããã°ã©ãã³ã°(partial reprogramming)ãã人ã«é©çšãã詊éšã§ãã ãéšåçãªããã°ã©ãã³ã°ãšã¯ã 2012幎ããŒãã«è³ãåè³ããå±±äžäŒžåŒ¥ææã®ãå±±äžå åããå¿çšããæè¡ã现èãå®å šã«åæåããã®ã§ã¯ãªããäžéšã ããªã»ããããŠãè¥ãç¶æ ã®æ©èœããåãæ»ãããšãç®æããŸããããŠã¹å®éšã§ã¯ãèŠç¥çµã®åçãèåããçµç¹ã®æ©èœå埩ãå ±åãããŠããŸããã ãä»åã®è©Šéšã®å¯Ÿè±¡ã å¯Ÿè±¡çŸæ£ã¯ NAION(éåèçæ§åéšèè¡æ§èŠç¥çµç)ãççŒãçªç¶èŠãã«ãããªãç æ°ã§ãçŸåšã¯æå¹ãªæ²»çæ³ãã»ãŒååšããŸãããER-100ã¯å察ã®å¥åžžãªçŒã«æäžããèŠç¥çµã®çްèããè¥ãç¶æ ãã«æ»ããŠä¿è·ããããšãçããŸããPhase 1ã¯å®å šæ§ã®ç¢ºèªãäž»ç®çã§ãã ããªãéèŠãã ãããŸã§èåç ç©¶ã¯åç©å®éšäžå¿ã§ããã人äœã§ã®å®å šæ§ããŒã¿ãåããã°ãèåããæ²»ç察象ããšããŠæ±ãç ç©¶å šäœãæ¬¡ã®æ®µéã«é²ã¿ãŸããäžæ¹ã§ããªããã°ã©ãã³ã°ã¯å¶åŸ¡ã誀ããšããåãªã¹ã¯ããããæ éãªèгå¯ãå¿ èŠãªé åã§ããããŸãã åºå ž: - Lifespan.io (2026幎2æ) - Fight Aging! (2026幎2æ) â»æ¬èšäºã¯æ å ±æäŸãç®çãšãããã®ã§ã蚺æãæ²»çæ¹éã¯å¿ ã䞻治å»ã«çžè«ããŠãã ããã

First Human Cellular Reprogramming Trial Cleared by the FDA
Life Biosciences' trial of cellular reprogramming aimed at age-related vision diseases has received a go-ahead from the FDA. We spoke with the companyâs CSO.
lifespan.io
話é¡ã«ãªã£ãŠããéºäŒåæ€æ»ãããã詊ããŠã¿ãŸãããåŸæ¶²ãéãã ãã§ãããããªäœè³ªã®åŸåãåºãŠãããã€ã§ãã çµæã¯é¢çœãã£ããã§ããããªã¹ã¯ãé«ãäœããšèšãããŠãããããã©ãåãæ¢ããã°ããã®ãæ£çŽããåãããŸããã§ããããããŸã§åŸåã§ãã£ãŠèšºæã§ã¯ãªãããšããåæã¯çè§£ããŠããã€ããã§ãããã¿ãªããã¯ããããçµæãšã©ãä»ãåã£ãŠããŸããã
è «çå ç§ã§åããŠããŸãã å°éã®å€ã®é åïŒããžã¿ã«ãã«ã¹ãäºé²ãªã©ïŒã®ãã¥ãŒã¹ã远ãããã«ãªã£ãŠãæ£è ãããšã®éè«ã®åŒãåºããå¢ããŸãããææ°ã®è©±é¡ãç¥ã£ãŠãããšãçžæã話ãããããã«ããŠãããæ°ãããŸãã å°éã«éãããããåºãç¥ãããšããã®ã¯ãã®ä»äºã§ãæ¡å€å€§äºã ãªãšæããŠããŸãã
ãã¥ãŒã¹ããŸãšãèšäºã ãèªãã§ãããšãã©ãããŠãèŠåºãã®å°è±¡ã«åŒã£åŒµãããŠããŸããšæè¿æããŠããŸããå ã®è«æããã¬ã¹ãªãªãŒã¹ãŸã§é¡ãçãã€ãããã®ã§ãããè±èªã®è«æãæ¯å粟èªããã®ã¯æ£çŽããã©ãã§ãã ã¢ãã¹ãã©ã¯ããšå³ã ãå ã«èŠããšããä¿¡é Œã§ããäºæ¬¡ãœãŒã¹ã䜵çšãããšããã¿ãªãããå®è·µããŠããçŸå®çãªããæ¹ãããã°å ±æããŠãããããšå¬ããã§ãã
ãã®ã³ãã¥ããã£ãèŠãå§ããã°ããã§ãããCRISPRãšããã¯ã¿ãŒãšãçšèªã®ããŒãã«ãé«ãã§ããã åå¿è åãã«çšèªããããã解説ããã¹ã¬ãããšããããšå©ãããªãšæããŸãããã¿ãªããæåã¯ã©ããã£ãŠæ £ããŠãããŸãããã
å°ãåãŸã§ã¯ãã¥ãŒã¹ã远ãã ãã ã£ãã®ã§ãããæè¿ã¯ããããªæ¹ã®è³ªåãçµéšè«ãå¢ããŠãã³ã¡ã³ãæ¬ãŸã§èªã¿èŸŒãã§ããŸããŸãã å°éã®æ¹ã®è£è¶³ãäžå¯§ã§å©ãã£ãŠããŸããèªåãçè§£ãæµ ããªãã«ãããããªãããšãçŽ çŽã«è³ªåããŠããããšæããŸããããããããããããé¡ãããŸãã
é ãäœã«ããŸãéºäŒã®ç æ°ããããšä»æ¥ç¥ããŸãããéåã®åãããã¯èããããšããããŸããããé ã§ãç æ°ã«ãªããšã¯ã æ®æ®µã®é£äºã§ã¬ããŒããããã«é ãå€ããšèª¿ã¹ãŠåºãŠããŸããããå¥åº·ãªäººãªãæ°ã«ããããå¿ èŠã¯ãªããã§ããããéºäŒæ§ã®ãã®ãšãé£äºã®è©±ã¯ãŸãå¥ãªã®ããªãšæãã€ã€æžã蟌ãã§ã¿ãŸããã
ãèŠåºããããã¯å¯è±ªãè³ãããèåãæ²»ããç ç©¶ ããŸã¹ãã¢ã«ããã³ããã«ã㌠â ã·ãªã³ã³ãã¬ãŒã®å€§å¯è±ªãã¡ãæ°ååãã«ãæããŠããæèåã»é·å¯¿ç ç©¶ããããããå®éã®æ²»éšããŒã¿ã§è©äŸ¡ãããæ®µéã«å ¥ããŸããã ãèŠåºããäœãèµ·ããŠããã 现èãªããã°ã©ãã³ã°ïŒçްèãè¥ãç¶æ ã«å·»ãæ»ãæè¡ïŒããèåãã现èãåãé€ãã¢ãããŒãããåç©å®éšãã人ã§ã®è©Šéšãžç§»ãã€ã€ãããŸããLife Biosciences瀟ã¯2026幎6æãèŠç¥çµã®çްèãªããã°ã©ãã³ã°æ²»çã§åããŠæ£è ãžã®æäžãè¡ã£ããšå ¬è¡šããŸããã ãèŠåºããæåŸ ãšçŸå®ã®ã®ã£ãã å·šé¡ã®è³éã«å¯Ÿãã人ã§ã寿åœãå»¶ã³ãããèåãé転ããããšèšŒæããè¬ã¯ãŸã ååšããŸãããå®å šæ§ã®ç¢ºèªãå§ãŸã£ãã°ããã§ããããŠã¹ã§å¹ããŠã人ã§åãçµæãåºããšã¯éãããé·å¯¿ã®æ€èšŒã«ã¯é·ã幎æãããããŸãã ãèŠåºããæ³šç®ãããç¹ è³éãšãã€ããå è¡ããŠããåéã ãããããããããåºãŠããèšåºããŒã¿ãå·éã«èªãç®ãåãããŸãã â»ãã®èšäºã¯æ å ±æäŸãç®çãšãããã®ã§ã蚺æãæ²»çæ¹éã¯å¿ ã䞻治å»ã«çžè«ããŠãã ããã åºå ž: AxiosïŒ2026-06-18ïŒãSilicon CanalsãLife Biosciencesçºè¡š
www.axios.com
ãã®ã³ãã¥ããã£ãè峿·±ã話é¡ãå€ãã®ã§ãããæ£çŽãªãšããå°éçšèªã§ã€ãŸããããšããããããŸããå¡©åºãšãå€ç°ãšãããªããšãªãåãã£ãã€ããã§ã人ã«èª¬æã§ããªãã åãããªãèšèãåºãŠãããããã®éœåºŠèª¿ã¹ãŠã¡ã¢ããããã«ããŠããã®ã§ãããçãããªãã®å匷æ³ãããã°å ±æããŠãããããšå¬ããã§ãã
å»çç³»ã®ä»äºãããŠããŸãããèªåã®å°éããå€ããé åã®ãã¥ãŒã¹ã¯æ£çŽãã£ããã¢ããã远ãã€ããŸããããã®ã³ãã¥ããã£ã®èšäºã¯å°éçšèªãäžæ®µããããããŠãããã®ã§ãå ¥å£ãšããŠå©ãã£ãŠããŸããã¿ãªããã¯æ®æ®µã©ãã§äžæ¬¡æ å ±ã远ã£ãŠããŸãããããããã®ãœãŒã¹ãããã°ç¥ãããã§ãã
ãã€ãªç³»ã®ãã¥ãŒã¹ã£ãŠãäžçåããç»æçããšããèšèãããåºãŠããŸããããæåŸ ããããªãäžæ¹ã§ãæ¿èªåã®æ®µéã ã£ããã察象æ£è ãéãããŠãããããããšãå€ããšæããŸãã ä»åã®in vivo CRISPRã確ãã«ããã話ã ãšæãã®ã§ãããèšäºèªäœãã1åã§ç涯ã¯ãããã確èªããæ®µéããæ¿èªããŸã 審æ»åããšãã¡ããšéãåºããŠããŠãéã«å¥œæãæã¡ãŸãããé床ã«ç œããªãæ å ±æºã¯è²Žéã§ããã
ãããããã¥ãŒã¹ã芪ã«è©±ããšãéºäŒåãããããªããŠæãããšããåå¿ãè¿ã£ãŠããŸãã ä»çµã¿ãäžå¯§ã«èª¬æããŠããSFçãªã€ã¡ãŒãžãå ã«ç«ã£ãŠããŸãããã§ã å°éçšèªã䜿ããã«äŒããè¯ãèšãåããããã°ç¥ãããã§ããçããã¯èº«è¿ãªäººã«ã©ã話ããŠããŸããã
æè¿ãé·å¯¿ãšãèåãå·»ãæ»ãã£ãŠè©±ãããèŠãããŸãããéæã¡ãäœååãæè³ããŠãã£ãŠèããšããããæä»£ã«ãªã£ããªãšæãåé¢ãæ¬åœã«å¹ãã®ããªãšããæ°æã¡ããããŸãã å®éã®ãšãããããããç ç©¶ã£ãŠä»ã©ã®ãããã®æ®µéãªãã§ããããã詳ããæ¹ããããçŽ äººã«ããããããã«æããŠã»ããã§ãã
éºäŒåæ²»çãšãå šç¶è©³ãããªãã®ã§ããããã¥ãŒã¹ãé¢çœããŠç»é²ããŠã¿ãŸãããå°éçšèªãå€ããŠæ¯åæ€çŽ¢ããªããèªãã§ããŸãã åãããã«éå°éã§èªãã§ããæ¹ããŸããïŒåãããªãåèªããã£ããšããã¿ãªããã©ããã£ãŠèª¿ã¹ãŠããã®ãåèã«ãããã§ãã
ããæ°ã¶æã现èãè¥è¿ããããšãèåãé転ãããã¿ãããªè©±é¡ãããèŠãããããã«ãªã£ãæ°ãããŸããå°ãåãŸã§SFã£ãœãå°è±¡ã ã£ãã®ã«ã倧ããªè£œè¬äŒç€ŸãŸã§é¢ãã£ãŠããŠãããšèããŠé©ããŸããã ããããã®ã£ãŠå®éã«ç§ãã¡ã䜿ããããã«ãªãã®ã¯äœå¹Žãããå ãªãã§ããããã詳ããæ¹ãããããã£ããã§ããã®ã§æèŠãæããŠã»ããã§ãã
ãããã®å»çç³»èšäºã¯å 容ã倧ããã ã£ãããéã«å€ãã£ããããããšãå€ããŠãã©ããä¿¡ããã°ãããè¿·ããŸããä»åã®iPSã®è©±ããåºå žãåŠäŒçºè¡šãªã®ãèŠå¶åœå±ã®çºè¡šãªã®ãã§éã¿ãéãæ°ãããŸãã çãããæ®æ®µãä¿¡é Œã§ããäžæ¬¡æ å ±ãšããŠåç §ããŠãããµã€ããæ©é¢ãããã°æããŠãã ããã
å»ççµæžåŠã®ç ç©¶ãããŠãã西æã§ããæ¥å¹Žã®ISPORïŒåœéå»è¬çµæžã»ã¢ãŠãã«ã ç ç©¶åŠäŒïŒã«åå ãããã®ã§ãããæž¡èªè²»ïŒåå è²»ïŒå®¿æ³è²»ã§50äžåè¿ããããããã§ãã 倧åŠã®ç ç©¶è²»ã ãã§ã¯è¶³ãããä»ã®è³éæºãæ¢ããŠããŸãã ãããŸã§ç§ã䜿ã£ãããšããããã®ïŒ ã»ç§ç è²»ïŒåºç€CïŒã®æ è²»æ ã»æå±åŠäŒã®æµ·å€æŽŸé£å©æ ã»å€§åŠã®æµ·å€åºåŒµæ¯æŽå¶åºŠ 質åïŒ 1. äŒæ¥ããã®å©æéãåããŠããæ¹ã¯ããŸããïŒå©ççžåã®ç®¡çã¯ã©ããããŠããŸããïŒ 2. è¥æç ç©¶è åãã®ãã©ãã«ã°ã©ã³ãã§ããããã¯ãããŸããïŒ 3. æè¿ã¯ãªã³ã©ã€ã³åå ã§ãååãšããæèŠããããŸããã察é¢åå ã®ã¡ãªãããã©ãèããŸããïŒ ç¹ã«è¥æã®æ¹ã®çµéšè«ããèããããã§ãããããããé¡ãããŸãã